

Literatur

1. Porst M, von der Lippe E, Leddin J, Anton A, Wengler A, Breitzkreuz J, Schüssler K, Brückner G, Schröder H, Gruhl H, Plaß D, Barnes B, Busch MA, Haller S, Hapke U, Neuhauser H, Reitzle L, Scheidt-Nave C, Schlotmann A, Steppuhn H, Thom J, Ziese T, Rommel A: The burden of disease in Germany at the national and regional level—results in terms of disability-adjusted life years (DALY) from the BURDEN 2020 study. *Dtsch Arztebl Int* 2022; 119: 785–92. DOI: 10.3238/arztebl.m2022.0314
2. Stovner LJ, Andree C. 2010. Prevalence of headache in Europe: A review for the Eurolight project. *Journal of Headache and Pain*, 11(4):289–299 DOI: 10.1007/s10194-010-0217-0.
3. Steiner TJ, Stovner LJ, Birbeck GL. 2013. Migraine: The seventh disabling. *Cephalalgia*, 33(5):289–290 DOI: 10.1177/0333102412473843.
4. Laurrell K, Larsson B, Eeg-Olofsson O. 2004. Prevalence of headache in Swedish schoolchildren, with a focus on tension-type headache. *Cephalalgia*, 24(5):380–388 DOI: 10.1111/j.1468-2982.2004.00681.x.
5. Sillanpää M, Piekala P, Kero P. 1991. Prevalence of headache at preschool age in an unselected child population. *Cephalalgia*, 11:239–242.
6. Arruda MA, Bigal ME. 2012. Migraine and migraine subtypes in preadolescent children Association with school performance. *Neurology*, 79:1881–1888.
7. Endres H, Herb M, Kaufmann-Kolle P, Neitemeier S, Schroeter K, Wunsch A. 2020. Kopfschmerz-report 2020 Prävalenz, Pillen und Perspektiven.
8. Krause, L., Sarganas, G., Thamm, R. et al. Kopf-, Bauch- und Rückenschmerzen bei Kindern und Jugendlichen in Deutschland. *Bundesgesundheitsbl* 62, 1184–1194 (2019). <https://doi.org/10.1007/s00103-019-03007-8>
9. Nieswand V, Richter M, Berner R, von der Hagen M, Klimova A, Roeder I, Koch T, Sabatowski R, Gossrau G. The prevalence of headache in German pupils of different ages and school types. *Cephalalgia*. 2019 Jul;39(8):1030-1040. doi: 10.1177/0333102419837156. Epub 2019 Mar 18. PMID: 30884960.
10. Arruda MA, Bigal ME. 2012. Migraine and migraine subtypes in preadolescent children Association with school performance. *Neurology*, 79:1881–1888
11. Zaranek L, Sobe H, Richter M, Hübler A, Berner R, von der Hagen M, Koch T, Sabatowski R, Klimova A, Goßrau G. Geschlechtsspezifische Ergebnisse des Dresdner Kinder- und Jugendkopfschmerzprogrammes DreKiP [Gender-specific results of the Dresden children and adolescents headache program DreKiP]. *Schmerz*. 2023 Sep 22. German. doi: 10.1007/s00482-023-00756-z. Epub ahead of print. PMID: 37737282
12. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. (2018). *Cephalalgia*, 38(1), 1-211. doi:10.1177/0333102417738202
13. Blankenburg, M., Schroth, M., & Braun, S. (2019). [Chronic Headache in Children and Adolescents]. *Klin Padiatr*, 231(1), 14-20. doi:10.1055/a-0710-5014
14. Genizi J, Khourieh Matar A, Schertz M, Zelnik N, Srugo I. Pediatric mixed headache -The relationship between migraine, tension-type headache and learning disabilities - in a clinic-based sample. *J Headache Pain*. 2016;17:42. doi: 10.1186/s10194-016-0625-x. Epub 2016 Apr 22. PMID: 27102119; PMCID: PMC4840135
15. Schipper et al. (2012). "Acute confusional migraine: our knowledge to date". *Expert Rev Neurother*. 2012 Mar;12(3):307-14. doi: 10.1586/ern.12.4
16. Farooq et al. (2017). "Alice in Wonderland Syndrome: A Historical and Medical Review" *Pediatr Neurol*. 2017Dec;77:5-11. doi: 10.1016/j.pediatrneurol.2017.08.008.
17. Gelfand, A. (2015). "Episodic Syndromes that may be associated with migraine: a.k.a. "the childhood periodic syndromes". *Headache*. 2015 November ; 55(10): 1358–1364. doi:10.1111/head.12624.
18. Diener, H. C., Holle, D., Solbach, K., & Gaul, C. (2016). Medication-overuse headache: risk factors, pathophysiology and management. *Nat Rev Neurol*, 12(10), 575-583. doi:10.1038/nrneurol.2016.124
19. Schor LI, Pearson SM, Shapiro RE, Zhang W, Miao H, Burish MJ. Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire. *Headache*. 2021 Nov;61(10):1511-1520. doi: 10.1111/head.14237. Epub 2021 Nov 28. PMID: 34841518.
20. Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. *Headache*. 2012 Jan;52(1):99-113. doi: 10.1111/j.1526-4610.2011.02028.x. Epub 2011 Nov 11. PMID: 22077141.
21. Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ. Epidemiology, burden and clinical spectrum of cluster headache: a global update. *Cephalalgia*. 2023 Sep;43(9):3331024231201577. doi: 10.1177/03331024231201577. PMID: 37728577.
22. Kelly M, Strelzik J, Langdon R, DiSabella M. Pediatric Headache: Overview. *Curr Opin Pediatr*. 2018;30(6):748-754. Derosier FJ, Lewis D, Hershey AD, et al. Random-ized trial of sumatriptan and naproxen sodium combination in adolescent migraine. *Pediatrics* 2012; 129: e1411-e1420
23. Kropp, P., Ebinger, F., & Evers, S. (2007). *Wenn Kindern der Kopf weh tut: Rat und Hilfe bei Kopfschmerzen und Migräne*. Stuttgart: Urania.
24. Dresler, T., Meyer, B., & Kropp, P. (2017). [Non-pharmacological migraine treatment - A practice-oriented summary]. *MMW Fortschr Med*, 159(10), 59-63. doi:10.1007/s15006-017-9709-z
25. Sobe H, Richter M, Berner R, von der Hagen M, Hähner A, Röder I, Koch T, Sabatowski R, Klimova A, Gossrau G. Functional improvement in children and adolescents with primary headache after an interdisciplinary multimodal therapy program: the DreKiP study. *J Headache Pain*. 2022 Aug 25;23(1):109. doi: 10.1186/s10194-022-01481-1. PMID: 36008766; PMCID: PMC9404663.
26. Oskoui, M., Pringsheim, T., Billingshurst, L., Potrebic, S., Gersz, E. M., Gloss, D., . . . Hershey, A. D. (2019). Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Headache*, 59(8), 1144-1157. doi:10.1111/head.13625
27. Cayir A, Turan MI, Tan H. Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. *Braz J Med Biol Res*. 2014 Apr;47(4):349-54. doi: 10.1590/1414-431x20143606. Epub 2014 Apr 8. PMID: 24714817; PMCID: PMC4075301.
28. Fallah R, Sarraf Yazd S, Sohrevardi SM. Efficacy of Topiramate Alone and Topiramate Plus Vitamin D3 in the Prophylaxis of Pediatric Migraine: A Randomized Clinical Trial. *Iran J Child Neurol*. 2020 Fall;14(4):77-86. PMID: 33193786; PMCID: PMC7660031.
29. Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. *Curr Drug Saf*. 2015;10(2):132-5. doi: 10.2174/1574886309666140605114614. PMID: 24909684.
30. <https://www.embryotox.de/arzneimittel/details/ansicht/medikament/paracetamol>
31. <https://www.dmgk.de/files/dmgk.de/Empfehlungen/Leitlinien-Amendmend%20zur%20Leitlinie%20Akuttherapie%20und%20Prophylaxe%20der%20Migra%CC%88ne%20vom%2004.01.2024.pdf>
32. Richter M, Gruhl E, Lautenschläger E, Müller T, Schumann F, Skiera D, Theisinger A, Zimmer U, Berner R, von der Hagen M, Sabatowski R, Hähner A, Gossrau G. DreKiP – ein ambulantes Therapieprogramm für Kinder und Jugendliche mit Kopfschmerzen [DreKiP - an outpatient treatment program for children and adolescents with headache]. *Schmerz*. 2018 Feb;32(1):17-29. German. doi: 10.1007/s00482-017-0245-7. PMID: 28956173.